Humana Inc (NYSE:HUM) Holdings Decreased by Cerebellum GP LLC

Cerebellum GP LLC lessened its stake in shares of Humana Inc (NYSE:HUM) by 64.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 188 shares of the insurance provider’s stock after selling 345 shares during the period. Cerebellum GP LLC’s holdings in Humana were worth $50,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Norges Bank acquired a new position in Humana during the 4th quarter worth about $402,117,000. Millennium Management LLC lifted its holdings in Humana by 254.8% during the 4th quarter. Millennium Management LLC now owns 503,066 shares of the insurance provider’s stock worth $144,118,000 after buying an additional 361,263 shares during the period. Ceredex Value Advisors LLC lifted its holdings in Humana by 31.8% during the 1st quarter. Ceredex Value Advisors LLC now owns 957,094 shares of the insurance provider’s stock worth $255,111,000 after buying an additional 230,671 shares during the period. BlackRock Inc. lifted its stake in shares of Humana by 1.6% in the 1st quarter. BlackRock Inc. now owns 12,190,049 shares of the insurance provider’s stock valued at $3,242,553,000 after purchasing an additional 186,997 shares during the period. Finally, Calamos Advisors LLC lifted its stake in shares of Humana by 114.4% in the 1st quarter. Calamos Advisors LLC now owns 306,086 shares of the insurance provider’s stock valued at $81,419,000 after purchasing an additional 163,339 shares during the period. Hedge funds and other institutional investors own 92.61% of the company’s stock.

NYSE HUM traded up $11.06 on Friday, hitting $291.25. 2,058,846 shares of the stock were exchanged, compared to its average volume of 1,139,136. The firm has a market cap of $39.33 billion, a P/E ratio of 20.02, a PEG ratio of 1.16 and a beta of 0.87. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.40. Humana Inc has a fifty-two week low of $225.65 and a fifty-two week high of $355.88. The firm has a 50-day simple moving average of $258.65.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, May 1st. The insurance provider reported $4.48 EPS for the quarter, beating the consensus estimate of $4.30 by $0.18. The firm had revenue of $16.11 billion during the quarter, compared to the consensus estimate of $15.67 billion. Humana had a net margin of 2.99% and a return on equity of 20.77%. Humana’s revenue for the quarter was up 12.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.36 EPS. Analysts forecast that Humana Inc will post 17.48 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a $0.55 dividend. The ex-dividend date is Thursday, June 27th. This represents a $2.20 annualized dividend and a yield of 0.76%. Humana’s dividend payout ratio is currently 15.12%.

Several equities analysts have recently issued reports on the company. SunTrust Banks upped their target price on Markel to $1,100.00 and gave the company a “hold” rating in a report on Thursday, May 2nd. Morgan Stanley upgraded to an “overweight” rating and set a GBX 400 ($5.23) target price on the stock in a research report on Friday. ValuEngine upgraded Valmont Industries from a “sell” rating to a “hold” rating in a research report on Friday. Credit Suisse Group reiterated a “buy” rating and set a $19.50 target price on shares of Infineon Technologies in a report on Thursday, May 2nd. Finally, Oppenheimer lowered their target price on shares of Littelfuse from $215.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the stock. Humana presently has an average rating of “Buy” and a consensus price target of $336.42.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Story: What is Depreciation?

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.